Cannabinoid-containing plant extracts as neuroprotective agents

1. A method of treating a patient suffering from a condition selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, frontotemporal dementia, prion disease, Lewy body dementia, progressive supranuclear palsy, vascular dementia, normal pressure hydrocephalus, traumatic spinal cord injury, HIV dementia, alcohol induced neurotoxicity, Down's syndrome and epilepsy consisting essentially of administering to said patient a therapeutically effective amount of a pharmaceutical formulation consisting essentially of an extract of Cannabis sativa , and wherein the extract of Cannabis sativa is obtained by supercritical or subcritical extraction with CO2, and is either

(a) a Cannabis sativa L. plant extract where a major cannabinoid is tetrahydrocannabinol (THC), and the extract consists essentially of

i) from 67.3-87.7% (w/w) of cannabinoid-containing components consisting essentially of the major cannabinoid; a minor cannabinoid; and one or more other cannabinoids; and

ii) from 12.3-32.7% (w/w) of non-cannabinoid components consisting essentially of terpenes; sterols; triglycerides; alkanes; squalene; tocopherol; carotenoids; chlorophyll; flavonoid; glycosides and alkaloids, or

(b) a Cannabis sativa L. plant extract where a major cannabinoid is cannabidiol (CBD) and the extract consists essentially of

i) from 65.8-95.5% (w/w) of cannabinoid-containing components consisting essentially of the major cannabinoid; a minor cannabinoid; and one or more other cannabinoids; and

ii) from 7.5-34.2% (w/w) of non-cannabinoid components consisting essentially of terpenes; sterols; triglycerides; alkanes; squalene; tocopherol; carotenoids; chlorophyll; flavonoid; glycosides and alkaloids.